No Data
No Data
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Avadel Pharmaceuticals and Nference Announce Publication of Real-World Data in Sleep Advances
H.C. Wainwright Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Maintains Target Price $27
Avadel Pharmaceuticals Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Craig-Hallum Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating
Craig-Hallum Remains a Buy on Avadel Pharmaceuticals (AVDL)